Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Triamcinolone
Drug ID BADD_D02271
Description Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis.[L8255] Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain,[L8264] or first line as a topical treatment of corticosteroid responsive dermatoses.[L8249] Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957.[L8243] In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval[L38973] - for the treatment of patients with macular edema associated with uveitis.[L38963]
Indications and Usage For the treatment of perennial and seasonal allergic rhinitis.
Marketing Status Discontinued
ATC Code A01AC01; C05AA12; D07AB09; D07XB02; H02AB08; R01AD11; R03BA06; S01BA05
DrugBank ID DB00620
KEGG ID D00385
MeSH ID D014221
PubChem ID 31307
TTD Drug ID D03BLF
NDC Product Code 22552-0003; 46439-8701; 38779-0051; 51927-1049
Synonyms Triamcinolone | Volon | Aristocort
Chemical Information
Molecular Formula C21H27FO6
CAS Registry Number 124-94-7
SMILES CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Malignant melanomaSerotransferrinP02787T026173015380; 2737997; 3919942; 6850583; 2788234; 2788497; 3297308; 6424929; 2439521; 6454570; 3049518; 6983291; 8826092; 6273246
Malignant melanomaInsulinP01308T828413015380; 2737997; 3919942; 6850583; 2788234; 2788497; 3297308; 6424929; 2439521; 6454570; 3049518; 6983291; 8826092; 6273246
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dysmenorrhoea21.01.01.002--
Dyspepsia07.01.02.001--
Dysphonia22.02.05.005; 19.19.03.002; 17.02.08.0040.000126%
Dyspnoea22.02.01.004; 02.01.03.0020.000822%
Ear infection11.01.05.001; 04.03.01.006--Not Available
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.001--Not Available
Embolism venous24.01.01.003--Not Available
Endophthalmitis11.01.06.003; 06.04.05.0090.002340%
Epistaxis24.07.01.005; 22.04.03.0010.000253%
Erythema23.03.06.0010.000506%Not Available
Euphoric mood19.04.02.006--
Exophthalmos06.09.04.001; 05.02.02.002--Not Available
Eye disorder06.08.03.0010.000253%Not Available
Eye infection11.01.06.001; 06.04.05.0070.000126%
Eye inflammation06.04.05.0020.000379%Not Available
Eye pain06.08.03.0020.000126%
Eye swelling06.08.03.0030.000126%Not Available
Facial pain08.01.08.0120.000126%
Fat embolism24.01.01.012; 12.01.08.003--Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Flushing08.01.03.025; 24.03.01.002; 23.06.05.0030.000696%
Folliculitis23.09.04.007; 11.01.12.018--
Fungal infection11.03.05.0010.000126%Not Available
Gait disturbance17.02.05.016; 08.01.02.0020.000316%
Glaucoma06.03.01.002--
Glucose tolerance impaired14.06.02.001; 05.06.02.001--
Glycosuria20.02.01.005--
Haemoglobin13.01.05.018--Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 9 Pages